Related references
Note: Only part of the references are listed.Clinical Activity of Gemcitabine Plus Pertuzumab in Platinum-Resistant Ovarian Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer
Sharmila Makhija et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Phase II Trial of Pertuzumab and Trastuzumab in Patients With Human Epidermal Growth Factor Receptor 2-Positive Metastatic Breast Cancer That Progressed During Prior Trastuzumab Therapy
Jose Baselga et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Strongly Enhanced Antitumor Activity of Trastuzumab and Pertuzumab Combination Treatment on HER2-Positive Human Xenograft Tumor Models
Werner Scheuer et al.
CANCER RESEARCH (2009)
Modulation of HER3 Is a Marker of Dynamic Cell Signaling in Ovarian Cancer: Implications for Pertuzumab Sensitivity
Yoko Nagumo et al.
MOLECULAR CANCER RESEARCH (2009)
Beyond chemotherapy: targeted therapies in ovarian cancer
Timothy A. Yap et al.
NATURE REVIEWS CANCER (2009)
Cancer statistics, 2008
Ahmedin Jemal et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2008)
Pertummab - Humanized anti-HER2 monoclonal antibody HER dimerization inhibitor oncolytic
S. P. Langdon et al.
DRUGS OF THE FUTURE (2008)
A phase I study of lapatinib in combination with carboplatin in women with platinum sensitive recurrent ovarian carcinoma
Kristopher J. Kimball et al.
GYNECOLOGIC ONCOLOGY (2008)
The emerging role of epidermal growth factor receptor inhibitors in ovarian cancer
M. J. Palayekar et al.
INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER (2008)
The oncogene HER2: its signaling and transforming functions and its role in human cancer pathogenesis
M. M. Moasser
ONCOGENE (2007)
Drug therapy: Trastuzumab - Mechanism of action and use in clinical practice
Clifford A. Hudis
NEW ENGLAND JOURNAL OF MEDICINE (2007)
Sensitivity to pertuzumab (2C4) in ovarian cancer models: cross-talk with estrogen receptor signaling
Peter Mullen et al.
MOLECULAR CANCER THERAPEUTICS (2007)
Clinical activity of Pertuzumab (rhuMAb 2C4), a HER dimerization inhibitor, in advanced ovarian cancer: Potential predictive relationship with tumor HER2 activation status
Michael S. Gordon et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
2C4, a monoclonal antibody against HER2, disrupts the HER kinase signaling pathway and inhibits ovarian carcinoma cell growth
N Takai et al.
CANCER (2005)
Multicenter, randomized phase II trial of oral CI-1033 for previously treated advanced ovarian cancer
S Campos et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Phase I safety, pharmacokinetics, and clinical activity study of lapatinib (GW572016), a reversible dual inhibitor of epidermal growth factor receptor tyrosine kinases, in heavily pretreated patients with metastatic carcinomas
HA Burris et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Combination treatment with erlotinib and pertuzumab against human tumor xenografts is superior to monotherapy
T Friess et al.
CLINICAL CANCER RESEARCH (2005)
ERBB receptors and cancer: The complexity of targeted inhibitors
NE Hynes et al.
NATURE REVIEWS CANCER (2005)
Phase I clinical study of pertuzumab, a novel HER dimerization inhibitor, in patients with advanced cancer
DB Agus et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Cancer incidence and mortality in Europe, 2004
P Boyle et al.
ANNALS OF ONCOLOGY (2005)
Blockade of epidermal growth factor- or heregulin-dependent ErbB2 activation with the anti-ErbB2 monoclonal antibody 2C4 has divergent downstream signaling and growth effects
JG Jackson et al.
CANCER RESEARCH (2004)
Phase 2 trial of single-agent gemcitabine in platinum-paclitaxel refractory ovarian cancer
M Markman et al.
GYNECOLOGIC ONCOLOGY (2003)
Ovarian cancer: Strategies for overcoming resistance to chemotherapy
R Agarwal et al.
NATURE REVIEWS CANCER (2003)
Phase II study of gemcitabine in recurrent platinum-and paclitaxel-resistant ovarian cancer
G D'Agostino et al.
GYNECOLOGIC ONCOLOGY (2003)
Structure of the extracellular region of HER2 alone and in complex with the Herceptin Fab
HS Cho et al.
NATURE (2003)
Evaluation of monoclonal humanized anti-HER2 antibody, trastuzumab, in patients with recurrent or refractory ovarian or primary peritoneal carcinoma with overexpression of HER2: A phase II trial of the Gynecologic Oncology Group
MA Bookman et al.
JOURNAL OF CLINICAL ONCOLOGY (2003)
Targeting ligand-activated ErbB2 signaling inhibits breast and prostate tumor growth
DB Agus et al.
CANCER CELL (2002)
Untangling the ErbB signalling network
Y Yarden et al.
NATURE REVIEWS MOLECULAR CELL BIOLOGY (2001)
Share Paper
